The invisible burden of multiple sclerosis: neuropsychiatric presentations and clinical pharmacology challenges
Academic Journal of Neuropsychiatry and Neuropsychology · 2026
DOI: 10.51271/ajnn-0056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academic Journal of Neuropsychiatry and Neuropsychology, 2026. Verfasst von Mehmet Hamamcı.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic central nervous system disease in which inflammation, demyelination, and neurodegeneration play interconnected roles. Successful MS management is not limited solely to suppressing inflammation. Early recognition of psychiatric presentations and meticulous planning of psychopharmacological interventions are essential. A strong multidisciplinary collaboration among neurologists, psychiatrists, and pharmacologists will alleviate the mental burden of the disease and minimize pharmacological morbidity. To enhance quality of life and long-term treatment success, there is an urgent need for comprehensive clinical guidelines that address this intersection.
Zitieren
APA
Hamamcı, M. (2026). The invisible burden of multiple sclerosis: neuropsychiatric presentations and clinical pharmacology challenges. Academic Journal of Neuropsychiatry and Neuropsychology. https://doi.org/10.51271/ajnn-0056
Vancouver
Hamamcı M. The invisible burden of multiple sclerosis: neuropsychiatric presentations and clinical pharmacology challenges. Academic Journal of Neuropsychiatry and Neuropsychology. 2026. doi:10.51271/ajnn-0056
BibTeX
@article{Hamamc2026,
author = {Hamamcı, Mehmet},
title = {The invisible burden of multiple sclerosis: neuropsychiatric presentations and clinical pharmacology challenges},
journal = {Academic Journal of Neuropsychiatry and Neuropsychology},
year = {2026},
doi = {10.51271/ajnn-0056}
}
EUVIMED